A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...
AgWeb

Study finds Pivot Bio PROVEN® 40 Increases Grower Revenue

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...

Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain

Gossamer Bio (NASDAQ:GOSS) reported top-line results from PROSERA, its global phase III registrational study evaluating inhaled seralutinib in patients with pulmonary arterial hypertension (PAH). Comp ...

Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation

Study represents a significant advancement in Grove’s Bionic Biologics™ platform – CHICAGO--(BUSINESS WIRE)--February 24, 2026-- Grove Biopharma, ...
STAT

Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval

Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.
STAT

What to expect from Gossamer Bio’s late-stage lung disease study

Gossamer Bio will be reporting the outcome of a late-stage study in pulmonary arterial hypertension. Here's what to know.
Seeking Alpha

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Analysis of Annovis Bio's lead product, buntanetap, tested in neurodegenerative diseases suggests questionable efficacy, in our opinion. Recent topline data from the PD phase 3 study shows no efficacy ...
Tampa Free Press on MSN

Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study

San Diego-based Gossamer Bio released long-awaited Phase 3 data today for its drug seralutinib, revealing a complex set of results that both challenged and encouraged researchers. The PROSERA study, ...
BioSpace

Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study

A patient has died in a mid-stage study of MacroGenics’ bispecific antibody lorigerlimab in gynecologic cancers, prompting ...